Companion Medical started selling its smart insulin pen in the U.S. today, according to the San Diego, Calif.-based company.
The InPen system, which combines an insulin injector pen and a smartphone app, is compatible with Eli Lilly‘s (NYSE:LLY) Humalog and Novo Nordisk‘s (NYSE:NVO) Novolog fast-acting insulin.
Companion Medical’s InPen tracks insulin dosing, automatically sending data to the user’s phone. The system can also calculate and recommend optimal dosing, monitor insulin temperature, remind the user when to take insulin and generate reports for healthcare providers.
“I am pleased to announce the commercial launch of InPen. The InPen system is a significant step toward true integrated diabetes management,” CEO Sean Saint said in prepared remarks. “Our team has worked diligently to develop a solution for people living with diabetes who want the benefits of an insulin pump without the cost or burden of being tethered to a device.”
The InPen app, which is compatible with iOS, integrates glucose data from blood glucose monitors using the Apple Health app. The company is working on an app for Android systems and said it hopes to release the app in the second quarter of 2018.
